SYS | | 0029046 |
LBL | | 00000naa^^22^^^^^^^^450 |
005 | | 20090702090841.9 |
100 | | $a 20090615a2009 m y0sloy0103 ba |
101 | 0- | $a eng $d eng |
102 | | $a SK |
200 | 1- | $a Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy $f Z. Kleibl ... [et al.] |
215 | | $c ilustr. (aj fareb.), grafy, obr., tab. |
320 | | $a Bibliogr. odkazy |
320 | | $a Res. angl. |
463 | -1 | $1 001 sllk_un_cat*0028544 $1 011 $a 0028-2685 $1 200 1 $a Neoplasma $e journal of experimental and clinical oncology $f Cancer Research Institute of the Slovak Academy of Sciences $v Vol. 56, no. 4 (2009), s. 303-316 $1 210 $a Bratislava $c AEPress $d 2009 $1 215 $a s. 279-370 |
541 | 1- | $a Vplyv variantov kódujúcich sekvencie génu dihydropyrimidín dehydrogenázy (DPYD) na vývoj toxicity spojenej s fluoropyrimidínom u pacientov s vysokým stupňom toxicity a u pacientov s výbornou toleranciou chemoterapie fluoropyrimidínom $z slo |
606 | 1- | $3 sllk_un_auth*d005472 $a fluorouracil $x analógy a deriváty $x toxicita $x účinky nežiaduce $2 mesh |
606 | 1- | $3 sllk_un_auth*d011743 $a pyrimidíny $2 mesh |
606 | 1- | $3 sllk_un_auth*d005796 $a gény $x účinky liekov $2 mesh |
606 | 2- | $3 sllk_un_auth*d004252 $a analýza DNA, mutačná $2 mesh |
606 | 2- | $3 sllk_un_auth*d006239 $a haplotypy $2 mesh |
606 | 2- | $3 sllk_un_auth*d004358 $a farmakoterapia $x účinky nežiaduce $2 mesh |
606 | 2- | $3 sllk_un_auth*d055106 $a štúdia celogenómová asociačná $2 mesh |
610 | 2- | $a fluoropyrimidíny |
610 | 2- | $a 5-fluorouracil |
610 | 2- | $a gén dihydropyrimidín dehydrogenázy |
610 | 2- | $a varianty génu |
701 | -1 | $3 sllk_un_auth*p0061136 $a Kleibl $b Zdeněk $p Ústav biochemie a experimentální onkologie 1. LF UK, Praha $4 070 |
701 | -1 | $3 sllk_un_auth*0010290 $a Fidlerová $b J. $p Ústav biochemie a experimentální onkologie 1. LF UK, Praha $4 070 |
701 | -1 | $3 sllk_un_auth*0001856 $a Kleiblová $b Petra $p Institute of Biochemistry and Experimental Oncology $4 070 |
701 | -1 | $3 sllk_un_auth*0008134 $a Kormunda $b Stanislav $p Institute of Social Medicine, Medical Faculty of Charles University, Pilsen $4 070 |
701 | -1 | $3 sllk_un_auth*0010291 $a Bílek $b M. $p Institute of Forensic Medicine and Toxicology, Charles University in Prague, 1st Faculty of Medicine and General Teaching Hospital, Prague $4 070 |
701 | -1 | $3 sllk_un_auth*0010292 $a Boušková $b K. $p Ústav biochemie a experimentální onkologie 1. LF UK, Praha $4 070 |
701 | -1 | $3 sllk_un_auth*0001855 $a Ševčík $b Jan $p Institute of Biochemistry and Experimental Oncology, Prague $4 070 |
701 | -1 | $3 sllk_un_auth*p0027803 $a Novotný $b Jan $p Onkologická klinika 1. LF UK a VFN, Praha $4 070 |
801 | -0 | $a SK $b BA006 $c 20090615 $g AACR2 |